JP2011513468A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011513468A5 JP2011513468A5 JP2010550202A JP2010550202A JP2011513468A5 JP 2011513468 A5 JP2011513468 A5 JP 2011513468A5 JP 2010550202 A JP2010550202 A JP 2010550202A JP 2010550202 A JP2010550202 A JP 2010550202A JP 2011513468 A5 JP2011513468 A5 JP 2011513468A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- hydroxy
- carboxamide
- compound
- fibrosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 32
- 150000003839 salts Chemical class 0.000 claims description 22
- 150000004677 hydrates Chemical class 0.000 claims description 9
- 239000012453 solvate Substances 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 35
- 201000010099 disease Diseases 0.000 claims 31
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 125000001424 substituent group Chemical group 0.000 claims 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 6
- 230000001684 chronic effect Effects 0.000 claims 6
- -1 heteroalicyclic Chemical group 0.000 claims 6
- 230000005764 inhibitory process Effects 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 239000001301 oxygen Substances 0.000 claims 6
- 230000002062 proliferating effect Effects 0.000 claims 6
- 208000024891 symptom Diseases 0.000 claims 6
- 125000002723 alicyclic group Chemical group 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- 206010016654 Fibrosis Diseases 0.000 claims 4
- 208000019693 Lung disease Diseases 0.000 claims 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 4
- 230000001154 acute effect Effects 0.000 claims 4
- 230000000747 cardiac effect Effects 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 230000004064 dysfunction Effects 0.000 claims 4
- 230000014509 gene expression Effects 0.000 claims 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- 230000003211 malignant effect Effects 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 230000001575 pathological effect Effects 0.000 claims 4
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 239000011593 sulfur Substances 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 125000002950 monocyclic group Chemical group 0.000 claims 3
- 230000009826 neoplastic cell growth Effects 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000036487 Arthropathies Diseases 0.000 claims 2
- 208000033116 Asbestos intoxication Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000000668 Chronic Pancreatitis Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000026372 Congenital cystic kidney disease Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 206010012434 Dermatitis allergic Diseases 0.000 claims 2
- 208000003037 Diastolic Heart Failure Diseases 0.000 claims 2
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims 2
- 201000009273 Endometriosis Diseases 0.000 claims 2
- 201000005569 Gout Diseases 0.000 claims 2
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 208000037357 HIV infectious disease Diseases 0.000 claims 2
- 206010019668 Hepatic fibrosis Diseases 0.000 claims 2
- 102100022537 Histone deacetylase 6 Human genes 0.000 claims 2
- 101000899330 Homo sapiens Histone deacetylase 6 Proteins 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 208000012659 Joint disease Diseases 0.000 claims 2
- WWGBHDIHIVGYLZ-UHFFFAOYSA-N N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester Chemical compound C1=CC(NC(=O)OC(C)(C)C)=CC=C1C1=CC(C(=O)NCCCCCCC(=O)NO)=NO1 WWGBHDIHIVGYLZ-UHFFFAOYSA-N 0.000 claims 2
- 208000003510 Nephrogenic Fibrosing Dermopathy Diseases 0.000 claims 2
- 206010067467 Nephrogenic systemic fibrosis Diseases 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 206010033649 Pancreatitis chronic Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims 2
- 108700019146 Transgenes Proteins 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 206010067269 Uterine fibrosis Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 206010003441 asbestosis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 229960002092 busulfan Drugs 0.000 claims 2
- 230000009787 cardiac fibrosis Effects 0.000 claims 2
- 230000004663 cell proliferation Effects 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 230000007882 cirrhosis Effects 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 201000006828 endometrial hyperplasia Diseases 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 208000010706 fatty liver disease Diseases 0.000 claims 2
- 230000000893 fibroproliferative effect Effects 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 238000001415 gene therapy Methods 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
- 230000003463 hyperproliferative effect Effects 0.000 claims 2
- 230000001506 immunosuppresive effect Effects 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- 201000006938 muscular dystrophy Diseases 0.000 claims 2
- KOWFSHAXTWICEJ-UHFFFAOYSA-N n-hydroxy-2-(2-pyridin-2-ylacetyl)-3,4-dihydro-1h-isoquinoline-6-carboxamide Chemical compound C1CC2=CC(C(=O)NO)=CC=C2CN1C(=O)CC1=CC=CC=N1 KOWFSHAXTWICEJ-UHFFFAOYSA-N 0.000 claims 2
- 230000001613 neoplastic effect Effects 0.000 claims 2
- 210000005036 nerve Anatomy 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 229920000155 polyglutamine Polymers 0.000 claims 2
- 108010040003 polyglutamine Proteins 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- 201000003086 pulmonary systemic sclerosis Diseases 0.000 claims 2
- 201000002793 renal fibrosis Diseases 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 230000000717 retained effect Effects 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 239000004753 textile Substances 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- FFGHBIDHKTXOOX-UHFFFAOYSA-N 2-(cyclobutanecarbonyl)-n-hydroxy-3,4-dihydro-1h-isoquinoline-6-carboxamide Chemical compound C1CC2=CC(C(=O)NO)=CC=C2CN1C(=O)C1CCC1 FFGHBIDHKTXOOX-UHFFFAOYSA-N 0.000 claims 1
- WFHZMKJZIFOFHO-UHFFFAOYSA-N 2-(cyclopropanecarbonyl)-n-hydroxy-3,4-dihydro-1h-isoquinoline-6-carboxamide Chemical compound C1CC2=CC(C(=O)NO)=CC=C2CN1C(=O)C1CC1 WFHZMKJZIFOFHO-UHFFFAOYSA-N 0.000 claims 1
- LXGOUPFICUBCKC-UHFFFAOYSA-N 2-[4-(dimethylamino)butanoyl]-n-hydroxy-3,4-dihydro-1h-isoquinoline-6-carboxamide Chemical compound ONC(=O)C1=CC=C2CN(C(=O)CCCN(C)C)CCC2=C1 LXGOUPFICUBCKC-UHFFFAOYSA-N 0.000 claims 1
- ZEYQVXQOWHMCHJ-UHFFFAOYSA-N 2-acetyl-n-hydroxy-3,4-dihydro-1h-isoquinoline-6-carboxamide Chemical compound ONC(=O)C1=CC=C2CN(C(=O)C)CCC2=C1 ZEYQVXQOWHMCHJ-UHFFFAOYSA-N 0.000 claims 1
- FYVMHJORQVOYJN-UHFFFAOYSA-N 2-n-benzyl-6-n-hydroxy-3,4-dihydro-1h-isoquinoline-2,6-dicarboxamide Chemical compound C1CC2=CC(C(=O)NO)=CC=C2CN1C(=O)NCC1=CC=CC=C1 FYVMHJORQVOYJN-UHFFFAOYSA-N 0.000 claims 1
- RMCQHWFEAQDXLE-UHFFFAOYSA-N 3-methoxypropyl 6-(hydroxycarbamoyl)-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound ONC(=O)C1=CC=C2CN(C(=O)OCCCOC)CCC2=C1 RMCQHWFEAQDXLE-UHFFFAOYSA-N 0.000 claims 1
- XKLOKKBUZMCZMD-UHFFFAOYSA-N 6-n-hydroxy-2-n-(2-phenoxyethyl)-3,4-dihydro-1h-isoquinoline-2,6-dicarboxamide Chemical compound C1CC2=CC(C(=O)NO)=CC=C2CN1C(=O)NCCOC1=CC=CC=C1 XKLOKKBUZMCZMD-UHFFFAOYSA-N 0.000 claims 1
- IKFKPIABKPNWRN-UHFFFAOYSA-N 6-n-hydroxy-2-n-(3-methoxypropyl)-3,4-dihydro-1h-isoquinoline-2,6-dicarboxamide Chemical compound ONC(=O)C1=CC=C2CN(C(=O)NCCCOC)CCC2=C1 IKFKPIABKPNWRN-UHFFFAOYSA-N 0.000 claims 1
- NSFKWTULDQEGAJ-UHFFFAOYSA-N 6-n-hydroxy-2-n-[2-(1h-indol-3-yl)ethyl]-3,4-dihydro-1h-isoquinoline-2,6-dicarboxamide Chemical compound C1=CC=C2C(CCNC(=O)N3CC4=CC=C(C=C4CC3)C(=O)NO)=CNC2=C1 NSFKWTULDQEGAJ-UHFFFAOYSA-N 0.000 claims 1
- LJLQUYCLLFFWFJ-UHFFFAOYSA-N 6-n-hydroxy-2-n-methyl-3,4-dihydro-1h-isoquinoline-2,6-dicarboxamide Chemical compound ONC(=O)C1=CC=C2CN(C(=O)NC)CCC2=C1 LJLQUYCLLFFWFJ-UHFFFAOYSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- FMHNSFXSPVHSBT-UHFFFAOYSA-N n-hydroxy-2-(2-phenoxyacetyl)-3,4-dihydro-1h-isoquinoline-6-carboxamide Chemical compound C1CC2=CC(C(=O)NO)=CC=C2CN1C(=O)COC1=CC=CC=C1 FMHNSFXSPVHSBT-UHFFFAOYSA-N 0.000 claims 1
- GZHOAMUABILFRY-UHFFFAOYSA-N n-hydroxy-2-(2-pyridin-3-ylacetyl)-3,4-dihydro-1h-isoquinoline-6-carboxamide Chemical compound C1CC2=CC(C(=O)NO)=CC=C2CN1C(=O)CC1=CC=CN=C1 GZHOAMUABILFRY-UHFFFAOYSA-N 0.000 claims 1
- DCYDCRPXDRDALJ-UHFFFAOYSA-N n-hydroxy-2-(3-pyridin-3-ylpropanoyl)-3,4-dihydro-1h-isoquinoline-6-carboxamide Chemical compound C1CC2=CC(C(=O)NO)=CC=C2CN1C(=O)CCC1=CC=CN=C1 DCYDCRPXDRDALJ-UHFFFAOYSA-N 0.000 claims 1
- ANJKMAGFRNRVGE-UHFFFAOYSA-N n-hydroxy-2-(4-methylbenzoyl)-3,4-dihydro-1h-isoquinoline-6-carboxamide Chemical compound C1=CC(C)=CC=C1C(=O)N1CC2=CC=C(C(=O)NO)C=C2CC1 ANJKMAGFRNRVGE-UHFFFAOYSA-N 0.000 claims 1
- GFWUSIRIFATLPR-UHFFFAOYSA-N n-hydroxy-2-(4-phenylbenzoyl)-1,3-dihydroisoindole-5-carboxamide Chemical compound C1C2=CC(C(=O)NO)=CC=C2CN1C(=O)C(C=C1)=CC=C1C1=CC=CC=C1 GFWUSIRIFATLPR-UHFFFAOYSA-N 0.000 claims 1
- MNIUKFHPMNDFJT-UHFFFAOYSA-N n-hydroxy-2-(5-methoxy-1h-indole-2-carbonyl)-3,4-dihydro-1h-isoquinoline-6-carboxamide Chemical compound C1CC2=CC(C(=O)NO)=CC=C2CN1C(=O)C1=CC2=CC(OC)=CC=C2N1 MNIUKFHPMNDFJT-UHFFFAOYSA-N 0.000 claims 1
- DITWXLWZJSNRHH-UHFFFAOYSA-N n-hydroxy-2-(oxolane-3-carbonyl)-3,4-dihydro-1h-isoquinoline-6-carboxamide Chemical compound C1CC2=CC(C(=O)NO)=CC=C2CN1C(=O)C1CCOC1 DITWXLWZJSNRHH-UHFFFAOYSA-N 0.000 claims 1
- BZBUHMSPUOWDNF-UHFFFAOYSA-N n-hydroxy-2-[2-(1h-indol-3-yl)acetyl]-3,4-dihydro-1h-isoquinoline-6-carboxamide Chemical compound C1=CC=C2C(CC(=O)N3CC4=CC=C(C=C4CC3)C(=O)NO)=CNC2=C1 BZBUHMSPUOWDNF-UHFFFAOYSA-N 0.000 claims 1
- BRMDCFGBUGQMJW-UHFFFAOYSA-N n-hydroxy-2-[2-(2-methoxyethoxy)acetyl]-3,4-dihydro-1h-isoquinoline-6-carboxamide Chemical compound ONC(=O)C1=CC=C2CN(C(=O)COCCOC)CCC2=C1 BRMDCFGBUGQMJW-UHFFFAOYSA-N 0.000 claims 1
- YKCWMTYPMRFNIH-UHFFFAOYSA-N n-hydroxy-2-[2-(2-methylimidazol-1-yl)acetyl]-3,4-dihydro-1h-isoquinoline-6-carboxamide Chemical compound CC1=NC=CN1CC(=O)N1CC2=CC=C(C(=O)NO)C=C2CC1 YKCWMTYPMRFNIH-UHFFFAOYSA-N 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 238000007347 radical substitution reaction Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08004661A EP2100879A1 (en) | 2008-03-13 | 2008-03-13 | Novel N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds |
| PCT/EP2009/052924 WO2009112550A1 (en) | 2008-03-13 | 2009-03-12 | Novel n-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011513468A JP2011513468A (ja) | 2011-04-28 |
| JP2011513468A5 true JP2011513468A5 (enExample) | 2014-02-27 |
Family
ID=39684426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010550202A Pending JP2011513468A (ja) | 2008-03-13 | 2009-03-12 | 新規なｎ−置換テトラヒドロイソキノリン／イソインドリンヒドロキサム酸化合物 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US8575193B2 (enExample) |
| EP (2) | EP2100879A1 (enExample) |
| JP (1) | JP2011513468A (enExample) |
| WO (1) | WO2009112550A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8624040B2 (en) | 2009-06-22 | 2014-01-07 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| EP2445340B1 (en) * | 2009-06-22 | 2016-05-18 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| WO2011106627A1 (en) | 2010-02-26 | 2011-09-01 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| US20110212969A1 (en) * | 2010-02-26 | 2011-09-01 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| WO2011130163A1 (en) | 2010-04-12 | 2011-10-20 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| WO2011146591A1 (en) | 2010-05-19 | 2011-11-24 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| WO2012027564A1 (en) | 2010-08-26 | 2012-03-01 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| WO2012031993A1 (en) * | 2010-09-09 | 2012-03-15 | F. Hoffmann-La Roche Ag | Novel n-hydroxy-benzamides for the treatment of cancer |
| CN103200936B (zh) * | 2010-09-09 | 2015-03-11 | 霍夫曼-拉罗奇有限公司 | 用于治疗癌症的新n-羟基苯甲酰胺类化合物 |
| US8765773B2 (en) | 2010-10-18 | 2014-07-01 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| US8778931B2 (en) * | 2010-12-22 | 2014-07-15 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| JP6053795B2 (ja) * | 2011-09-19 | 2016-12-27 | シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニＳｉｇｍａ−Ｔａｕ Ｉｎｄｕｓｔｒｉｅ Ｆａｒｍａｃｅｕｔｉｃｈｅ Ｒｉｕｎｉｔｅ Ｓｏｃｉｅｔａ Ｐｅｒ Ａｚｉｏｎｉ | 強力なｈｄａｃ阻害剤としてのラクタムを有する新しいチオ誘導体、及び治療剤としてのその使用 |
| WO2013041407A1 (en) * | 2011-09-19 | 2013-03-28 | Cellzome Ag | Hydroxamic acids as hdac6 inhibitors |
| EP2771321A4 (en) * | 2011-10-28 | 2015-04-08 | Chong Kun Dang Pharm Corp | HYDROXAMATE DERIVATIVES FOR HDAC INHIBITORS AND PHARMACEUTICAL COMPOSITIONS THEREWITH |
| BR112014029301A2 (pt) | 2012-05-25 | 2017-07-25 | Berg Llc | métodos de tratamento de síndrome metabólica através de modulação da proteína choque térmico (hsp) 90-beta |
| US10167258B2 (en) | 2013-12-13 | 2019-01-01 | The Board Of Regents Of The University Of Texas System | Inhibitors of mitochondrial pyruvate dehydrogenase kinase isoforms 1-4 and uses thereof |
| AU2015269054A1 (en) | 2014-06-06 | 2017-01-12 | Berg Llc | Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta |
| CN107801396B (zh) | 2015-02-02 | 2021-10-22 | 福马治疗股份有限公司 | 作为hdac抑制剂的3-芳基-4-酰氨基-二环[4,5,0]异羟肟酸 |
| WO2016126726A1 (en) | 2015-02-02 | 2016-08-11 | Forma Therapeutics, Inc. | Bicyclic [4,6,0] hydroxamic acids as hdac6 inhibitors |
| CN108368043B (zh) * | 2015-10-27 | 2022-11-29 | 台北医学大学 | 用于治疗及/或预防纤维化疾病的吲哚啉衍生物 |
| EP3472131B1 (en) | 2016-06-17 | 2020-02-19 | Forma Therapeutics, Inc. | 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors |
| TW201821105A (zh) | 2016-10-20 | 2018-06-16 | 美商弗瑪治療公司 | 使用ｈｄａｃ１１抑制劑之方法 |
| WO2018095260A1 (en) * | 2016-11-28 | 2018-05-31 | National Institute Of Biological Sciences, Beijing | Dihydroxyphenyl Sulfonylisoindoline Derivatives |
| US10357493B2 (en) | 2017-03-10 | 2019-07-23 | Selenity Therapeutics (Bermuda), Ltd. | Metalloenzyme inhibitor compounds |
| US11535607B2 (en) | 2018-04-20 | 2022-12-27 | Valo Health, Inc. | Isoindolines as HDAC inhibitors |
| CA3097696A1 (en) * | 2018-04-20 | 2019-10-24 | Valo Early Discovery, Inc. | Isoindolines as hdac inhibitors |
| CN108752316B (zh) * | 2018-07-18 | 2020-07-10 | 云南大学 | 四氢异喹啉-2-甲基苯并咪唑盐类化合物及其制备方法和应用 |
| US12215382B2 (en) * | 2019-03-01 | 2025-02-04 | The General Hospital Corporation | Liver protective MARC variants and uses thereof |
| US20220281814A1 (en) * | 2019-07-30 | 2022-09-08 | Eikonizo Therapeutics, Inc. | Hdac6 inhibitors and uses thereof |
| CN111808102B (zh) * | 2020-08-03 | 2021-12-31 | 南通大学 | 一种3-甲氧基-6,7-二氢-5H-吡咯并[3,4-b]吡啶盐酸盐及其合成方法 |
| CN117242056A (zh) * | 2021-03-26 | 2023-12-15 | 北京加科思新药研发有限公司 | 用作sting激动剂的新型化合物及其用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20020354A1 (es) * | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| CA2542096A1 (en) * | 2003-10-09 | 2005-04-21 | Aton Pharma, Inc. | Thiophene and benzothiophene hydroxamic acid derivatives |
| ES2239529B1 (es) | 2004-01-20 | 2006-10-01 | Universidad Autonoma De Madrid | Procedimiento de identificacion de los compuestos reguladores de la actividad tubulina desacetilasa de hdac6 y sus aplicaciones. |
| US7705017B2 (en) | 2004-05-03 | 2010-04-27 | En Vivo Pharmaceuticals, Inc. | Compounds for treatment of neurodegenerative diseases |
| ES2275400B1 (es) | 2005-04-20 | 2008-04-01 | Universidad Autonoma De Madrid | Uso de compuestos agonistas de la actividad tubulina desacetilasa de la proteina hdac6 en la elaboracion de composiciones farmaceuticas, dichas composiciones farmaceuticas y sus aplicaciones en el tratamiento de infecciones virales. |
| KR20080054417A (ko) * | 2005-09-27 | 2008-06-17 | 노파르티스 아게 | 카르복시아민 화합물 및 ｈｄａｃ 의존성 질환의 치료에있어서의 그의 용도 |
| US20070207950A1 (en) | 2005-12-21 | 2007-09-06 | Duke University | Methods and compositions for regulating HDAC6 activity |
| CN101484156B (zh) | 2006-05-03 | 2015-11-25 | 哈佛大学校长及研究员协会 | 组蛋白脱乙酰基酶和微管蛋白脱乙酰基酶抑制剂 |
| GB0612273D0 (en) | 2006-06-21 | 2006-08-02 | Friedrich Miescher Inst For Bi | Prevention of muscle atrophy |
-
2008
- 2008-03-13 EP EP08004661A patent/EP2100879A1/en not_active Ceased
-
2009
- 2009-03-12 EP EP09720660A patent/EP2274283A1/en not_active Withdrawn
- 2009-03-12 WO PCT/EP2009/052924 patent/WO2009112550A1/en not_active Ceased
- 2009-03-12 JP JP2010550202A patent/JP2011513468A/ja active Pending
- 2009-03-12 US US12/921,821 patent/US8575193B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011513468A5 (enExample) | ||
| WO2009112550A4 (en) | Novel n-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds | |
| JP6113285B2 (ja) | Ｂ型肝炎ウイルス感染症の治療及び予防用の６−アミノ酸ヘテロアリールジヒドロピリミジン | |
| US7790740B2 (en) | Imidazopyridine substituted tropane derivatives with CCR5 receptor antagonist activity for the treatment of HIV and inflammation | |
| TWI721016B (zh) | B型肝炎核心蛋白質調節劑 | |
| JP6056872B2 (ja) | イミダゾピリジン化合物 | |
| JP6294359B2 (ja) | スフィンゴシン−１−リン酸受容体アゴニスト、その製造方法及びそれらを活性成分として含有する医薬組成物 | |
| JP7126514B2 (ja) | アミノピリジン誘導体化合物の塩、その結晶形態、及びその調製プロセス | |
| US5684015A (en) | Imidazopyridines as pharmaceutical agents | |
| JP2009524670A5 (enExample) | ||
| JP5463592B2 (ja) | アデノシンａ１レセプターアンタゴニストとしての新規化合物 | |
| US20050267114A1 (en) | Triazaspiro[5.5]undecane derivatives and drugs comprising the same as the active ingredient | |
| WO2014033167A1 (en) | Fused bicyclic sulfamoyl derivatives and the use thereof as medicaments for the treatment of hepatitis b | |
| JP7627008B2 (ja) | ピロール化合物 | |
| WO1998008848A1 (en) | Imidazoquinazoline derivatives | |
| JP6893516B2 (ja) | ３−（（ヘテロ−）アリール）−８−アミノ−２−オキソ−１，３−ジアザ−スピロ−［４．５］−デカン誘導体 | |
| KR101830566B1 (ko) | 테트라히드로이소퀴놀린-1-온 유도체 또는 그의 염 | |
| EA018995B1 (ru) | Производные карбаматов алкилтиазолов, их получение и их применение в терапии | |
| RU2489432C2 (ru) | ТРИАЗОЛО[1,5-a]ХИНОЛИНЫ В КАЧЕСТВЕ ЛИГАНДОВ РЕЦЕПТОРА АДЕНОЗИНА А3 | |
| JP6781848B2 (ja) | 新規なピロロピリジン誘導体、その製造方法及び用途 | |
| US20040067955A1 (en) | Pyridazinone compound and pharmaceutical use thereof | |
| JP6416230B2 (ja) | 新規３，４−ジヒドロ−２ｈ−イソキノリン−１−オン及び２，３−ジヒドロ−イソインドール−１−オン化合物 | |
| JP2646405B2 (ja) | ビフェニルメタン誘導体カリウム塩及びこれを含有する医薬 | |
| JP2000239277A (ja) | イミダゾキナゾリン誘導体 | |
| HK1140676A (en) | Imidazopyridine substituted tropane derivatives with ccr5 receptor antagonist activity for the treatment of hiv and inflammation |